Lyra Therapeutics Inc (LYRA) FinancialsLYRALyra Therapeutics Inc

Evaluating the bottom line, Lyra Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -25032.00%, while the net margin is -23936.00%. These profitability ratios, combined with a Return on Equity (ROE) of -404.48%, provide a clear picture of how effectively LYRA converts its operational activities into shareholder value.

In the context of the broader market, LYRA competes directly with industry leaders such as INM and SPRC. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, LYRA's gross margin of 100.00% stands against INM's N/A and SPRC's 73.71%. Such benchmarking helps identify whether Lyra Therapeutics Inc is trading at a premium or discount relative to its financial performance.

In 2025/Q3, revenue dropped significantly to $25,000 (-87.18% YoY), net income fell to -$5,984,000 (-49.60% YoY), and EPS declined to -3.38 (-62.73% YoY). Gross margin remained flat at 100%. The financial performance indicates severe challenges in growth and profitability.